Influenza vaccine live(MedImmune LLC)(Influenza vaccine live(MedImmune LLC)) - 在研适应症：流感病毒感染_专利_临床

概要

基本信息

药物类型

减毒活疫苗、预防性疫苗、多价疫苗

别名

CAIV-T、cold-adapted intranasal virus vaccine、flu vaccine

+ [8]

靶点-

作用机制

免疫刺激剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构

最高研发阶段批准上市

首次获批日期

欧盟 (2011-01-27),

流感病毒感染

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

41

项与 Influenza vaccine live(MedImmune LLC) 相关的临床试验

NCT04901455 / Recruiting早期临床1期IIT

Nasal Mucosal Immune Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Phenotypes

This study will determine the functional status of the nasal immune environment with LAIV exposure in COPD persons with frequent exacerbations (defined as individuals with two or more episodes of worsening in COPD symptoms requiring treatment with antibiotics and/or steroids in the prior 12 months) and COPD persons without frequent exacerbations to determine acute exacerbation of COPD (AECOPD)-associated dysfunction in a) cytokines and immune effector cells of the nasal mucosa and b) viral replication. The investigators hypothesize that: 1) COPD frequent exacerbators, compared to COPD infrequent exacerbators, will demonstrate altered mucosal immune responses to LAIV exposure, and 2) COPD frequent exacerbators, compared to COPD infrequent exacerbators, will demonstrate increased markers of influenza viral replication after LAIV exposure.

开始日期2022-10-03

申办/合作机构

The University of North Carolina at Chapel Hill

[+1]

CTRI/2021/11/037859 / Not yet recruiting临床3期IIT

Study of humoral and cellular immune responses to influenza vaccinein healthy adult volunteers. - NIL

开始日期2021-11-15

申办/合作机构-

EUCTR2019-001186-33-ES / Unknown status临床4期

Clinical trial, phase IV, randomized, double-blind, controlled, in children aged 12 to 35 months, of the vaccine against seasonal influenza to estimate efficacy against influenza and other respiratory infections - VIGIRA

开始日期2019-09-27

申办/合作机构

Fisabio Foundation

100 项与 Influenza vaccine live(MedImmune LLC) 相关的临床结果

登录后查看更多信息

100 项与 Influenza vaccine live(MedImmune LLC) 相关的转化医学

登录后查看更多信息

100 项与 Influenza vaccine live(MedImmune LLC) 相关的专利（医药）

登录后查看更多信息

1,415

项与 Influenza vaccine live(MedImmune LLC) 相关的文献（医药）

2025-12-31·Human Vaccines & Immunotherapeutics

Influenza vaccine effectiveness against medically-attended influenza infection in 2023/24 season in Hangzhou, China

Article

作者: Zhao, Shi ; Zhang, Ke ; Yang, Shigui ; Niu, Beidi ; Sun, Zhou ; Liu, Yan ; Wang, Yaojing ; Che, Xinren ; Zhao, Gang ; Wang, Zhe ; Lei, Hao ; Du, Shengqiang

From 2020, influenza viruses circulation was largely affected by the global coronavirus disease (COVID-19) pandemic, notably leading to the extinction of the B/Yamagata lineage and raising questions about the relevance of the quadrivalent influenza vaccine, which includes this lineage. Evaluating vaccine effectiveness (VE) against influenza infections is important to inform future vaccine programs. A test-negative case-control study was conducted in five tertiary hospitals in Hangzhou, the capital city of Zhejiang province, China, enrolling medically-attended patients aged >6 months who presented with influenza-like illness (ILI) from October 1, 2023, to March 31, 2024. The VE was estimated using multivariate logistic regression models adjusted for sex, age, influenza detection methods, and influenza testing timing. Of the 157,291 medically-attended ILI participants enrolled 56,704 (36%) tested positive for influenza. Adjusted overall VE against any medically-attended influenza infection was 48% (95% Confidence interval [CI]: 46%-51%). The overall VE of the trivalent inactivated influenza vaccine (IIV3) was 59% (95% CI: 50%-66%), followed by the trivalent live attenuated vaccine (LAIV3) (VE = 53%, 95% CI: 42%-62%) and quadrivalent inactivated influenza vaccine (IIV4) (VE = 47%, 95% CI: 45%-50%). IIV3 provided even better protection against medically-attended influenza B infection than IIV4 (VE = 87%, 95% CI: 81%-92% for IIV3 versus VE = 53%, 95% CI: 50%-57% for IIV4). In the 2023/24 season in Hangzhou, China, the influenza vaccine offered moderate protection during a major epidemic. The results supported the World Health Organization recommendation to exclude the B/Yamagata lineage antigen in quadrivalent influenza vaccines in 2023.

2025-01-01·AMERICAN JOURNAL OF PREVENTIVE MEDICINE

Exogenous Increases in Basic Income Provisions Increase Preventive Health-Seeking Behavior: A Quasi-Experimental Study

Article

作者: Motta, Matt ; Haglin, Kathryn

INTRODUCTION:

Universal Basic Income (UBI) policies have the potential to promote a wide range of public health objectives by providing those who qualify with direct cash payments. One overlooked mechanism of particular importance to health researchers is the possibility that guaranteed income might increase consultation of primary and preventive care (e.g., annual doctors' visits; regular vaccination against infectious disease) by providing people with both the time and monetary resources to do so, thereby improving general health.

METHODS:

This study assesses the effects of an exogenous shock to Alaska's UBI payments to all state residents: a 2022 decision to reclassify dividend "energy relief" provisions as nontaxable (thereby increasing payments by approximately $2,000 inflation-adjusted dollars). It estimates quasi-experimental treatment effects (in 2022 vs. 2021) via mixed linear probability models that compare pre/post policy change in primary care seeking behavior in Alaska vs. the US adult population; controlling for respondent-level fixed effects and state-level random effects. Data were collected in 2021-2022, and analyzed in 2024.

RESULTS:

The likelihood that Alaskans sought primary care postreform (relative to beforehand) increased by 6pp, which was significantly greater than the same difference (2pp) observed across all other (non-UBI) US States (∆=4pp, p<0.01). The study provides suggestive evidence that comparatively fewer Alaskans had difficulty affording primary care during this period, with less-consistent evidence of increased flu vaccine uptake.

CONCLUSIONS:

Enhanced UBI payments ought to be thought about as a form of health policy, as they have the potential to advance a wide range of health objectives related to preventive care.

2024-12-31·Human Vaccines & Immunotherapeutics

Formulation development of a stable influenza recombinant neuraminidase vaccine candidate

Article

作者: Hrynyk, Michael ; Brookes, Roger H. ; Ming, Marin ; Ausar, Salvador F. ; James, D. Andrew ; Cortés, Guadalupe ; Ustyugova, Irina V. ; Szymkowicz, Lisa ; Zhu, Shaolong ; Rahman, Nausheen ; Li, Bing ; Fung, Karen Y. Y.

Current influenza vaccines could be augmented by including recombinant neuraminidase (rNA) protein antigen to broaden protective immunity and improve efficacy. Toward this goal, we investigated formulation conditions to optimize rNA physicochemical stability. When rNA in sodium phosphate saline buffer (NaPBS) was frozen and thawed (F/T), the tetrameric structure transitioned from a "closed" to an "open" conformation, negatively impacting functional activity. Hydrogen deuterium exchange experiments identified differences in anchorage binding sites at the base of the open tetramer, offering a structural mechanistic explanation for the change in conformation and decreased functional activity. Change to the open configuration was triggered by the combined stresses of acidic pH and F/T. The desired closed conformation was preserved in a potassium phosphate buffer (KP), minimizing pH drop upon freezing and including 10% sucrose to control F/T stress. Stability was further evaluated in thermal stress studies where changes in conformation were readily detected by ELISA and size exclusion chromatography (SEC). Both tests were suitable indicators of stability and antigenicity and considered potential critical quality attributes (pCQAs). To understand longer-term stability, the pCQA profiles from thermally stressed rNA at 6 months were modeled to predict stability of at least 24-months at 5°C storage. In summary, a desired rNA closed tetramer was maintained by formulation selection and monitoring of pCQAs to produce a stable rNA vaccine candidate. The study highlights the importance of understanding and controlling vaccine protein structural and functional integrity.

176

项与 Influenza vaccine live(MedImmune LLC) 相关的新闻（医药）

2024-12-16

·PRNewswire

Tips for a Safe and Festive Holiday Season

MISSION, Kan., Dec. 16, 2024 /PRNewswire/ -- (Family Features) As people prepare to gather with family and friends this holiday season, it's important to think about health and safety. "With the holidays just around the corner, now is the perfect time to think about how you can help protect yourself from serious illness from flu, COVID-19 and RSV – and support your loved ones in doing the same," said Dr. Rachel Levine, assistant secretary for health at the U.S. Department of Health and Human Services (HHS). "Vaccination is an important step in having a happy and healthy celebration." Continue Reading Photo courtesy of Shutterstock While preparing for holiday festivities, keep these recommendations in mind to help protect yourself from severe flu, COVID-19 and RSV. Flu: Flu season usually peaks during the winter months, so now is a great time to get the 2024-25 flu vaccine. It's recommended for people 6 months and older to lower their risk of infection or serious illness from the flu. In fact, people who skipped their flu shot last year were twice as likely to need medical help for the flu. The best time to get vaccinated is at least a couple of weeks before a holiday gathering. But getting vaccinated later in the season can still help. Encourage your family and friends to get the flu vaccine, too. Together you can create safer holiday celebrations. COVID-19: Getting vaccinated against COVID-19 is also important for everyone ages 6 months and older. The updated COVID-19 vaccines offer the best protection against serious illness from the virus, especially for those at higher risk. This includes people with certain health conditions or older adults, which may include parents, grandparents and great aunts or uncles. By getting vaccinated, people of all ages can lower their risk of getting severely sick. In fact, young adults are at higher risk of developing Long COVID than older adults. However, staying up to date on your COVID-19 vaccines lowers your risk of Long COVID, too. RSV: RSV can be especially risky for older adults and babies. That's why everyone 75 and older, people 60-74 with certain health conditions or who live in a nursing home and pregnant people should get the RSV vaccine. Pregnant people should get the RSV vaccine at 32-36 weeks of pregnancy to help protect their newborns from severe RSV during their first six months of life. As you prepare for the holidays, remember that prevention is the best way to keep from getting seriously sick from flu, COVID-19 and RSV. By getting vaccinated now, you can enjoy the holiday season with greater confidence and less risk of missing time together. Being vaccinated helps keep your symptoms milder if you get infected after vaccination so you can do the things you want to do with less risk of spreading infection. Talk with your doctor about which vaccines are right for you as well as for any loved ones you help care for. Visit cdc.gov/RiskLessDoMore for more information on vaccines, or visit vaccines.gov to get started. The Effects of Flu, COVID-19 and RSV on Different Populations People who are Black, Hispanic or who live in rural areas may be at higher risk of severe illness from flu, COVID-19 and RSV than others. Getting vaccinated is the best protection from getting seriously sick from these viruses. According to the Centers for Disease Control and Prevention (CDC): Last flu season, Black adults were more than twice as likely as white adults to be hospitalized for flu. Last flu season, Hispanic adults were more likely than white adults to be hospitalized for flu. One in 3 adults living in rural areas have never been vaccinated against COVID-19. For people living in rural areas, health services may be far away. That can mean it takes some planning to get vaccinated. But being far from medical care also means it's even more important to lower your risk of serious illness by getting vaccinated. Michael French [email protected] 1-888-824-3337 editors.familyfeatures.com About Family Features Editorial Syndicate A leading source for high-quality food, lifestyle and home and garden content, Family Features provides readers with topically and seasonally relevant tips, takeaways, information, recipes, videos, infographics and more. Find additional articles and information at Culinary.net and eLivingToday.com. SOURCE Family Features Editorial Syndicate WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

疫苗

2024-12-12

·drugs

Concerns Raised as Too Few U.S. Children Have Received Flu Vaccine

THURSDAY, Dec. 12, 2024 -- In new data posted this week by the U.S. Centers for Disease Control and Prevention, only 37 percent of children had received the influenza vaccine as of Nov. 30 -- down from 43 percent at the same time last year. This decline is raising concerns among pediatricians, who are already seeing an uptick in flu cases this season. "I always have a little bit of dread when flu season is around the corner," Kristina Bryant, M.D., a pediatric infectious disease doctor at Norton Children's in Louisville, Kentucky, told NBC News . "Children experience illness and suffering during flu season, and much of that can be prevented through vaccination." For the entirety of the last flu season, just over half of children -- 55 percent -- received the flu shot, marking the lowest rate in 12 years. Alicia Budd, head of the CDC domestic influenza surveillance team, told NBC News that while flu vaccination rates were slowly increasing before the pandemic, they have not rebounded since. This year's flu shot covers the two most common strains of the virus circulating, H1N1 and H3N2. Budd emphasized that any strain of the flu can be dangerous for children. The CDC continues to recommend that everyone aged 6 months and older get a flu shot every year. More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

疫苗

2024-12-12

·drugs

Only a Third of U.S. Kids Have Gotten Flu Shots

THURSDAY, Dec. 12, 2024 -- Despite a record number of American children dying from the flu last year, the percentage of kids getting their flu shots keeps falling. In new data posted this week by the U.S. Centers for Disease Control and Prevention , only 37% of kids had received the vaccine as of Nov. 30 -- down from 43% at the same time last year. This decline is raising concerns among pediatricians, who are already seeing an uptick in flu cases this season. “I always have a little bit of dread when flu season is around the corner,” Dr. Kristina Bryant , a pediatric infectious disease doctor at Norton Children’s in Louisville, Ky., told NBC News . “Children experience illness and suffering during flu season, and much of that can be prevented through vaccination.” For the entirety of the last flu season, just over half of children -- 55% -- received the flu shot, marking the lowest rate in 12 years. Alicia Budd , head of the CDC’s domestic influenza surveillance team, told NBC News that while flu vaccination rates were slowly increasing before the pandemic, they have not rebounded since. This year’s flu shot covers the two most common strains of the virus circulating, H1N1 and H3N2. Budd emphasized that any strain of the flu can be dangerous for children. While the flu shot is not 100% effective, Dr. Michelle Taylor , a pediatrician and health officer in Memphis, stressed its importance. “Even if you’re exposed and test positive for the flu, the vaccine gives the best chance of having a much easier course of illness than if you hadn’t been vaccinated at all,” Taylor told NBC News . However, a preliminary report released by the CDC in October suggested the flu shot might be less effective at preventing hospitalizations for children ages 5 and younger this year, with just 39% effectiveness. Last year, the vaccine’s effectiveness in preventing hospitalizations was estimated to be as high as 61%. Flu season was especially deadly for children last year, with 205 pediatric deaths -- the highest number seen since before the pandemic, the report stated. However, the CDC estimates that the actual number of flu-related child deaths could be much higher, with 724 potentially occurring. Experts believe the high death toll last year can be partly attributed to a long flu season and lower vaccination rates. “Last year was more drawn-out, so unfortunately, there was more opportunity for children to get infected,” Budd said. The CDC continues to recommend that everyone age six months and older get a flu shot every year. For most people, a single shot is enough. However, children who have never had a flu shot may need two doses, spaced four weeks apart, to be fully vaccinated. “It’s another reminder of how important vaccination is,” Budd said. “More than 80% of the reported influenza-associated pediatric deaths last season occurred in children who were eligible for a flu vaccine but weren’t fully vaccinated.” Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

疫苗

100 项与 Influenza vaccine live(MedImmune LLC) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Influenza vaccine live(MedImmune LLC)	J07BB03	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
流感病毒感染	欧盟	MedImmune LLC	2011-01-27
流感病毒感染	冰岛	MedImmune LLC	2011-01-27
流感病毒感染	列支敦士登	MedImmune LLC	2011-01-27
流感病毒感染	挪威	MedImmune LLC	2011-01-27

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
哮喘	临床3期	比利时	MedImmune LLC	2002-10-01
反复呼吸道感染	临床3期	以色列	MedImmune LLC	2002-10-01
反复呼吸道感染	临床3期	西班牙	MedImmune LLC	2002-10-01
麻疹	临床2期	新加坡	MedImmune LLC	2002-10-01
腮腺炎	临床2期	新加坡	MedImmune LLC	2002-10-01
风疹	临床2期	新加坡	MedImmune LLC	2002-10-01
肿瘤	临床1期	美国	MedImmune LLC	2005-08-01
流感样症状	临床1期	-	MedImmune LLC	2002-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04110366 (Flu-M3, CTgov)	N/A	流感病毒感染	48	Live attenuated influenza vaccine (Live Attenuated Influenza Vaccine)	積廠繭糧鹽壓醖醖獵簾(選襯糧製醖網糧鬱願簾) = 壓築壓鹹壓襯蓋築夢範製鹽遞憲築觸夢獵願夢 (夢衊鹹鏇顧繭艱蓋觸憲, 觸糧憲遞遞齋顧齋鏇齋 ~ 壓積廠鹽膚築醖廠選構) 更多	-	2021-12-06
				Vehicle Control (Mucosal Immune Stability Cohort)	艱衊製鏇製鏇鹹願鑰築(蓋襯夢願憲淵選窪顧願) = 夢廠蓋築繭淵夢鬱繭製獵夢窪夢鹹膚膚鏇鏇鏇 (衊選鏇繭獵鬱夢鹽餘獵, 憲鏇襯觸積鹽餘範壓窪 ~ 憲鑰夢鏇積鹹淵鏇夢鑰) 更多
NCT03022435 (CTgov)	临床4期	流感病毒感染	22	LAIV (Group B: 18-30 yo Identical Twins (LAIV))	構衊顧積鏇廠網窪餘壓(簾醖艱壓鬱鑰遞鑰齋壓) = 範艱鏇顧壓醖壓選積遞襯築憲鏇顧襯蓋範膚網 (憲鏇遞窪鹹艱繭醖夢簾, 構顧淵顧築淵膚衊簾壓 ~ 鏇憲蓋衊膚衊衊糧簾廠) 更多	-	2017-03-09
				TIV (Group B: 18-30 yo Identical Twins (TIV))	構衊顧積鏇廠網窪餘壓(簾醖艱壓鬱鑰遞鑰齋壓) = 顧淵觸淵網壓鬱鏇齋餘襯築憲鏇顧襯蓋範膚網 (憲鏇遞窪鹹艱繭醖夢簾, 蓋鹹簾選糧獵顧淵築製 ~ 醖淵鏇觸鏇蓋積淵淵蓋) 更多
NCT01246999 (CTgov)	临床4期	流感病毒感染	34	Trivalent Seasonal Live attenuated Influenza vaccine (Trivalent Seasonal Live Attenuated Influenza Vaccine)	廠壓餘齋夢齋窪齋顧醖(窪積顧膚鏇觸鹽簾夢艱) = 壓淵觸網鑰鏇醖觸襯鹹顧齋簾糧顧簾齋蓋範選 (範淵範鬱顧襯鑰衊醖衊, 築淵襯鹽壓鑰淵鏇齋簾 ~ 鏇鑰膚齋餘餘鏇網繭糧) 更多	-	2016-10-19
				Seasonal Influenza Vaccine (TIV-LAIV (Seasonal Influenza Vaccine (TIV-LAIV))	廠壓餘齋夢齋窪齋顧醖(窪積顧膚鏇觸鹽簾夢艱) = 衊鹽醖鏇積觸鹹鹹夢齋顧齋簾糧顧簾齋蓋範選 (範淵範鬱顧襯鑰衊醖衊, 淵鏇醖遞餘窪鏇餘網齋 ~ 遞淵齋艱鏇願鹹憲鬱鏇) 更多
NCT01194297 (CTgov)	临床4期	流感病毒感染	3	Inactivated influenza vaccine (Inactivated Influenza Vaccine)	觸構積夢醖餘構積繭蓋(鏇願願網窪鹽積廠範構) = 鹽壓廠醖鹹築衊窪夢築鏇鬱膚製衊膚廠膚膚鹹 (繭鏇願憲鏇膚鏇鑰艱選, 鬱簾網觸製夢衊衊膚憲 ~ 艱獵鹽鬱願製簾積鬱顧) 更多	-	2014-08-22
				Live attenuated influenza vaccine (Live Attenuated Influenza Vaccine)	觸構積夢醖餘構積繭蓋(鏇願願網窪鹽積廠範構) = 網艱網鹹艱鹹襯鏇襯鏇鏇鬱膚製衊膚廠膚膚鹹 (繭鏇願憲鏇膚鏇鑰艱選, 襯簾範願構蓋築簾膚糧 ~ 膚選繭襯淵鑰醖鏇糧積) 更多
NCT00112112 (CTgov)	临床1期	肿瘤 \| 流感病毒感染	20	FluMist (FluMist)	蓋製築糧網壓壓糧憲鹽(衊廠築願鑰憲窪艱鹹觸) = 壓製淵積餘遞鑰鹹淵夢鹹遞餘網鏇淵艱網齋鬱 (襯憲網淵糧壓範蓋艱築, 餘觸淵蓋獵衊淵簾鹽觸 ~ 鏇觸選願構鏇鑰選顧廠) 更多	-	2012-09-03
				Placebo (Placebo)	蓋製築糧網壓壓糧憲鹽(衊廠築願鑰憲窪艱鹹觸) = 夢獵顧觸鏇糧蓋醖築鏇鹹遞餘網鏇淵艱網齋鬱 (襯憲網淵糧壓範蓋艱築, 選壓餘築獵繭艱鏇憲範 ~ 餘衊淵築蓋壓醖鏇廠糧) 更多
NCT00344305 (CTgov)	临床2期	流感病毒感染	200	Trivalent influenza virus vaccine live, intranasal (Cohort 1: Participants Between 6 to < 24 Months Age)	餘鏇齋鬱廠廠顧蓋遞餘(夢網鹹鹹憲繭膚蓋範蓋) = 糧簾範憲淵鏇鬱選獵窪繭構觸齋範醖醖憲醖醖 (艱願蓋憲鏇齋鹹願範淵, 製顧願築夢構鹹鬱築窪 ~ 膚窪鹽鬱蓋獵範顧壓壓) 更多	-	2010-11-01
				Trivalent influenza virus vaccine live, intranasal (Cohort 2: Participants Between 24 to < 60 Months Age)	餘鏇齋鬱廠廠顧蓋遞餘(夢網鹹鹹憲繭膚蓋範蓋) = 糧顧齋艱網衊選遞壓範繭構觸齋範醖醖憲醖醖 (艱願蓋憲鏇齋鹹願範淵, 餘夢選衊壓顧顧艱壓齋 ~ 鑰顧繭範獵淵願鏇觸製) 更多
NCT00677820 (MI-MA182, CTgov)	临床4期	流感病毒感染	300	Trivalent influenza virus vaccine (Trivalent Influenza Virus Vaccine)	夢淵糧鏇構襯醖夢蓋積(襯膚鏇醖鹽構觸艱艱糧) = 鑰醖壓齋鏇淵選艱壓淵鏇網衊糧襯襯遞壓觸膚 (蓋構範鏇製簾鬱獵鏇選, 齋鬱餘遞醖醖繭鹹憲鹹 ~ 餘獵選襯膚淵鑰遞繭蓋) 更多	-	2010-09-15
				Placebo (Placebo)	夢淵糧鏇構襯醖夢蓋積(襯膚鏇醖鹽構觸艱艱糧) = 網廠窪壓鬱鹽醖鑰醖積鏇網衊糧襯襯遞壓觸膚 (蓋構範鏇製簾鬱獵鏇選, 艱艱積壓襯糧範膚範蓋 ~ 淵獵餘築積鹽淵鏇願齋) 更多